CXCL9 and breast cancer: Recently, an IFN-γ+ gene signature (IFNG, CD274, LAG3, and CXCL9) was reported to be associated with improved clinical outcomes of durvalumab treatment in patients with BC, highlighting the crucial role of IFN-γ in successful ICI treatment for BC [24].